Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.12. | Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward | 124 | GlobeNewswire (Europe) | Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially... ► Artikel lesen | |
APREA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
07.11. | Aprea Therapeutics GAAP EPS of -$0.64 | 1 | Seeking Alpha | ||
07.11. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
07.11. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
23.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.10. | Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit | 3 | GlobeNewswire (USA) | ||
09.10. | APRE stock touches 52-week low at $2.22 amid market challenges | 1 | Investing.com | ||
09.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.10. | Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development | 1 | GlobeNewswire (USA) | ||
09.09. | Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
04.09. | APRE stock touches 52-week low at $3.17 amid market challenges | 1 | Investing.com | ||
28.08. | Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
21.08. | Aprea Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
12.08. | Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M | 1 | Seeking Alpha | ||
12.08. | APRE stock touches 52-week low at $3.22 amid market challenges | 1 | Investing.com | ||
12.08. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08. | Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | 120 | GlobeNewswire (Europe) | Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 - no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash... ► Artikel lesen | |
12.08. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
17.06. | Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 | 148 | GlobeNewswire (Europe) | APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet... ► Artikel lesen | |
14.05. | Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update | 120 | GlobeNewswire (Europe) | U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CG ONCOLOGY | 30,040 | +3,19 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
QUANTUM-SI | 3,575 | +66,28 % | Pre-market Movers: Intrusion, SES AI, Solid Power, Quantum-Si, Rail Vision | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green Intrusion Inc. (INTZ) is up over 380% at $2.16.
SES... ► Artikel lesen | |
QIAGEN | 43,310 | +0,69 % | Biotech Report: Qiagen und Evotec leichter | (shareribs.com) Frankfurt / New York 20.12.2024 - Zum Ende der letzten Handelswoche des Jahres stehen die Biotechwerte unter Druck. Im deutschen Handel geht es für Evotec und Qiagen abwärts.Der DAX... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,390 | -3,52 % | Is Recursion Pharmaceuticals Stock a Millionaire Maker? | ||
TEMPUS AI | 35,120 | -0,48 % | Cathie Wood's ARK buys AMD and TEMPUS AI, sells ARCHER AVIATION | ||
NUVALENT | 80,30 | -2,14 % | Nuvalent-Direktor Shair verkauft Aktien im Wert von 167.565 US-Dollar | ||
EVOTEC | 8,535 | +1,49 % | Übernahmekandidaten 2025: Plug Power, Evotec, Desert Gold Aktie | Kommt es zur Übernahme von Plug Power oder droht ein Kurseinbruch? Letzteres ist in den kommenden Wochen möglich und Aktionäre müssen aufpassen. Ein heißer Übernahmekandidat im Goldsektor ist Desert... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 55,00 | +1,20 % | How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run | ||
DYNE THERAPEUTICS | 23,720 | -3,06 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
BIONTECH | 109,40 | -0,18 % | Biontech: 1,2 Milliarden Euro für Impfstoffvergleich in USA | MAINZ (dpa-AFX) - Der Impfstoffhersteller Biontech hat in den USA im Streit um Lizenzgebühren millionenschwere Vergleiche geschlossen. Insgesamt umgerechnet 1,2 Milliarden Euro wird das Unternehmen... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,790 | -3,23 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
CELCUITY | 13,840 | +5,81 % | Celcuity (NASDAQ:CELC) Trading Up 3.8% - Here's Why | ||
HUMACYTE | 5,500 | +3,97 % | Humacyte (NASDAQ:HUMA) Shares Up 6% - Here's What Happened | ||
RELAY THERAPEUTICS | 4,360 | -2,02 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
CANDEL THERAPEUTICS | 8,870 | -3,27 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen |